Immunome Stock Forward View - Polynomial Regression
| IMNM Stock | USD 23.27 0.16 0.69% |
Polynomial Regression is applied to Immunome's daily closing prices, and the resulting forecast is presented with accuracy metrics. Wide deviation between fitted and observed values suggests the model's assumptions may not match current market conditions. These values update automatically with each new closing price. The Polynomial Regression model projects Immunome at 23.48 for the next trading day, above the most recent closing price. This Polynomial Regression output is provided as analytical reference and does not constitute a trading recommendation.
Polynomial Regression Price Forecast For the 8th of May
Over a 90-day horizon, the Polynomial Regression model forecasts Immunome at 23.48 for the next trading day, with a mean absolute deviation of 0.57 , mean absolute percentage error of 0.03 , and sum of absolute errors of 35.38 .This represents a tight forecast with good short-term tracking of Immunome's price movement. This output is intended for short-term analytical reference.
Stock Forecast Pattern
| Backtest Immunome | Immunome Price Prediction | Research Analysis |
Forecasted Value
The projected range for Immunome reflects the model's ability to define credible downside and upside scenarios for the next trading day. Downside is estimated near 20.40 and upside near 26.56. The wide range indicates elevated uncertainty in short-term projections.
Model Predictive Factors
The table below summarizes the Polynomial Regression model's error metrics for Immunome stock. Lower MAD and MAPE values indicate tighter forecast accuracy. AIC measures relative model quality — lower values indicate less information loss and a better-fitting model. A large Bias suggests systematic over- or under-prediction.| AIC | Akaike Information Criteria | 119.3003 |
| Bias | Arithmetic mean of the errors | None |
| MAD | Mean absolute deviation | 0.5707 |
| MAPE | Mean absolute percentage error | 0.026 |
| SAE | Sum of the absolute errors | 35.384 |
Other Forecasting Options for Immunome
Immunome's daily price returns decompose into trend, seasonal, and residual components. Divergence between short-term and long-term averages in Immunome often signals an upcoming reversal or acceleration. Gap analysis of Immunome Stock data examines overnight jumps between Immunome's closing and opening prices.Immunome Related Equities
Immunome's market space within the Health Care space is illustrated by the firms listed below. Peer review on balance sheet metrics shows how Immunome's capital structure stacks up against similar firms. Sector-wide trends across this peer group split company-level factors from broader forces.
| Risk & Return | Correlation |
Immunome Market Strength Events
Market strength indicators for Immunome stock provide a framework for assessing security responsiveness. A rising Accumulation/Distribution line alongside rising price confirms institutional buying interest in Immunome. Median and Typical Price smooth out intraday extremes, providing a cleaner reference level for evaluating Immunome sessions.
Immunome Risk Indicators
Assessing Immunome's risk indicators is a structured way to evaluate the risk-return trade-off for immunome stock. The level of risk embedded in Immunome's feeds directly into exposure calibration. Comparing Immunome's downside variance to total variance reveals whether the risk profile is skewed toward losses.
| Mean Deviation | 2.23 | |||
| Standard Deviation | 3.09 | |||
| Variance | 9.54 |
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Immunome Short Properties
Short-interest data for Immunome reveals whether bearish conviction in the market is gaining traction. Comparing short sentiment with trend behavior, volume, and the broader market narrative provides a more grounded view.
| Common Stock Shares Outstanding | 87.35 million | |
| Cash And Short Term Investments | 653.48 million |